Healthware Group appoints Eugene Borukhovich as senior advisorDigital Health veteran Eugene Borukhovich has joined Healthware Group as senior advisor to its Media and Community business Share XHealthware Group appoints Eugene Borukhovich as senior advisorhttps://pharmaphorum.com/news/healthware-group-appoints-eugene-borukhovich-senior-advisor/
Navigating the patient maze – pharma’s evolving challengePharma companies are embracing patient centricity in drug development more than ever before. Over the last decade, leaders Share XNavigating the patient maze – pharma’s evolving challengehttps://deep-dive.pharmaphorum.com/magazine/communications-and-commercialisation/patient-pharma-engagement-drug-development/
Identifying And Engaging Digital Opinion LeadersDigital Opinion Leaders (DOLs) and KOLs overlap, but each group is unique. Unlike traditional KOLs, DOLs have a Share XIdentifying And Engaging Digital Opinion Leadershttps://pharmaphorum.com/partner-content/identifying-and-engaging-digital-opinion-leaders/
Launch excellence: escaping the complexity trapIQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex Share XLaunch excellence: escaping the complexity traphttps://pharmaphorum.com/sales-marketing/launch-excellence-escaping-the-complexity-trap/
It’s time to rethink the physician-pharma relationshipThe traditional sales channel for the pharmaceutical industry has centered on face-to-face interaction with its core target audience Share XIt’s time to rethink the physician-pharma relationshiphttps://deep-dive.pharmaphorum.com/magazine/communications-and-commercialisation/physician-pharma-relationships/
Actemra shortage spills over to include Sanofi’s rival KevzaraRoche’s Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to Share XActemra shortage spills over to include Sanofi’s rival Kevzarahttps://pharmaphorum.com/news/actemra-shortage-spills-over-to-include-sanofis-rival-kevzara/
Supernus bulks up its Parkinson’s portfolio with Adamas takeoverSupernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Share XSupernus bulks up its Parkinson’s portfolio with Adamas takeoverhttps://pharmaphorum.com/news/supernus-bulks-up-its-parkinsons-portfolio-with-adamas-takeover/
Refining digital collaborationPharmaceutical companies are traditionally more conservative with their approach to and incorporation of new technologies; however, prior to Share XRefining digital collaborationhttps://deep-dive.pharmaphorum.com/magazine/communications-and-commercialisation/pharma-hcp-digital-collaboration/
Closing pharma’s communication gap with patientsThe pharma industry has been talking about being patient-centric for years, but often that rhetoric hasn’t been accompanied Share XClosing pharma’s communication gap with patientshttps://deep-dive.pharmaphorum.com/magazine/communications-and-commercialisation/syneos-health-pharma-patient-communications/
